Researchers take a step closer to finding a treatment for a rare genetic neurodevelopmental condition
Original story from Texas Children’s Duncan Neurological Research Institute (TX, USA).
Modulating alternative splicing of the MECP2 gene has been identified as a potential therapeutic strategy for Rett syndrome.
A team of researchers at Texas Children’s Duncan Neurological Research Institute (NRI) and Baylor College of Medicine (both TX, USA) have reported a potential new approach to treat Rett syndrome, offering early promise for a rare neurodevelopmental disorder that currently has no cure.
“Rett syndrome is a rare genetic neurodevelopmental condition that causes a regression in development, typically after 6 to 18 months of normal growth, leading to severe impairments in motor skills, speech and communication,” commented corresponding author Huda Zoghbi, Director of the Duncan NRI and Distinguished Service Professor at Baylor. “The disorder primarily affects girls; about 1 in 10,000 live births.”
Rett syndrome is caused by loss-of-function mutations in the MECP2 gene, which is key for normal brain function as it modulates the levels of several genes regulating neurological functions. These mutations either lead to loss of the protein or encode a defective protein that cannot fulfill its normal function. Some of the disease-causing mutant MeCP2 proteins are less abundant and/or have decreased DNA binding, an essential function of this protein.
Mouse models of Rett syndrome show that the disorder is reversible – introducing normal MeCP2 protein in the brains of these mice reverses the symptoms. Importantly, researchers have shown that increasing the levels of a mutant MeCP2 protein that retains a little function also improves symptoms, including survival, motor coordination and respiratory abnormalities in mice.
“This is important because about 65% of patients with Rett syndrome have partially functional MeCP2 that either has decreased DNA binding or is less abundant than normal,” explained first author Harini Tirumala, graduate student of molecular and human genetics in the Zoghbi lab. “Working with mouse models and cells derived from patients with Rett syndrome, our study provides proof of concept that increasing the levels of mutant MeCP2 in patients with the condition could provide therapeutic benefit.”
Rare disease drug discovery: the technologies driving ‘orphan’ therapeutics forward
Here, we explore how innovations like AI and gene editing are changing the game in rare disease research by advancing drug discovery and development.
Understanding how the MECP2 gene works prompts a new idea
It’s not easy to develop therapeutics that modulate MeCP2 abundance. Too little MeCP2 causes Rett syndrome, yet too much MeCP2 causes a different neurological disorder, MECP2 Duplication Syndrome. Reaching this delicate balance has made it challenging to develop safe and effective treatments.
“We knew from previous studies that the brain normally produces two slightly different versions of the MeCP2 protein, known as E1 and E2,” Zoghbi shared. “These versions come from the same gene, which is processed one way to produce E1 and a different way for E2.”
Think of a gene as a recipe for a protein. The recipe for MeCP2 has four ingredients: e1, e2, e3 and e4. To make the MeCP2-E1 protein, cells only combine ingredients e1, e3 and e4. To make MeCP2-E2, cells combine all four ingredients, making ingredient e2 unique to this version of the protein. The brain produces both versions, but E1 predominates.
“We also knew that there have been no reports of Rett syndrome patients carrying mutations on E2 protein. Only mutations that disrupt E1 protein cause the condition,” Tirumala commented. “Studies in mice support this observation.”
“Altogether, we knew that MeCP2-E2 differs from MeCP2-E1 by a single ingredient in the gene, is less abundant than E1, is not associated with Rett syndrome and is not needed for MeCP2 function in the brain,” Tirumala noted. “This led us to hypothesize that guiding brain cells to skip the e2 ingredient would promote the production of more MeCP2-E1 protein in patients with Rett syndrome and improve disease outcomes. We tested our hypothesis in mice and in cells derived from patients with Rett-syndrome.”
First, the researchers genetically deleted ingredient e2 from the normal Mecp2 gene in mice and assessed the effect on the protein’s abundance and its neurological function. “We were pleased to find that this approach led to 50% to 60% increase of MeCP2 protein in normal mice,” Tirumala shared.
The researchers then applied the same approach to cells derived from patients with Rett syndrome carrying MECP2 mutations that reduce the abundance and activity of the protein. They deleted ingredient e2 from this mutant MECP2 gene and assessed the effect on the protein’s abundance and the characteristics of these cells. “We were excited to see that deleting ingredient e2 enhanced MeCP2 production,” Tirumala commented. “Importantly, depending on the severity of the mutation, these cells recovered part or all of their normal structure, their normal electrical activity and their ability to regulate the levels of other genes.”
Finally, the team assessed the therapeutic potential of this approach. Would a drug that blocks access to ingredient e2 increase abundance of the MeCP2 protein?
“We tested the value of morpholinos to enhance the production of MeCP2 protein in mice,” Tirumala explained. “Morpholinos are synthetic molecules designed, in this case, to prevent the production of MeCP2-E2 protein by blocking the access to the e2 ingredient. It was exciting to see that our morpholinos significantly increased MeCP2 protein in mice.”
“Our work lays the foundation and provides preclinical evidence for a therapeutic approach for Rett syndrome that increases MeCP2 and confers functional improvement,” Zoghbi concluded. “Although morpholinos themselves are not an option because of their toxicity, similar strategies, like antisense oligonucleotide therapies already used in other conditions, could potentially be developed for Rett syndrome.”
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source. Our press release publishing policy can be accessed here.